MannKind Corporation to Present at the June 2020 Lytham Part

[kite]

www.globenewswire.com/news-release/2020/06/17/2049771/0/en/MannKind-Corporation-to-Present-at-the-June-2020-Lytham-Partners-Virtual-Investor-Growth-Conference.html

WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET (9 am PT). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Pharm D.

A webcast of the presentation will be posted under the investors section of MannKind’s website under events & presentations or can be accessed at www.lythampartners.com/virtual. A replay of the presentation will be available following the event.

Management will also be participating in virtual one-on-one meetings with institutional investors on June 24, 2020. To arrange a meeting, please contact Robert Blum of Lytham Partners at [e-mail] or visit www.lythampartners.com/virtual.

[seanismorris]

Jun 17, 2020 16:00:55 GMT -5 kite said:

www.globenewswire.com/news-release/2020/06/17/2049771/0/en/MannKind-Corporation-to-Present-at-the-June-2020-Lytham-Partners-Virtual-Investor-Growth-Conference.html

WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET (9 am PT). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Pharm D.

A webcast of the presentation will be posted under the investors section of MannKind’s website under events & presentations or can be accessed at www.lythampartners.com/virtual. A replay of the presentation will be available following the event.

Management will also be participating in virtual one-on-one meetings with institutional investors on June 24, 2020. To arrange a meeting, please contact Robert Blum of Lytham Partners at [e-mail] or visit www.lythampartners.com/virtual.

I normally ignore these, but not this time.  Insider buying is a tell.  It’s a “legitimate” form of insider trading...


Hopefully, they’ll tell us something to support the run up in price this week.

[boytroy88]

Waiting on matt to chime in about this. In the past when MNKD attended this type of conference it's usually to solicit funds and there was always some sort of dilution. Will it be the same this time?

[porkini]

I've got audio - MC is 11-12 slides into presentation. I got into it late, about the 6th slide.

[porkini]

Sounded like MC said "we recently lost a specialty pharmacy but are working on a new one"?

[porkini]

5 analysts - 2 buy, 2 outperform, 1 overweight

[porkini]

"Thing that slows Afrezza down is just capital, if we had 200 reps we could do better..." paraphrase

[porkini]

"David Kendall just joined 2 years ago and it takes time to get data out there but it is beginning to happen..." paraphrase

[boytroy88]

Looks like he's tanking the stock..

[awesomo]

This presentation is awful.

[porkini]

My connection has been having a problem. Much of what I heard after coming in about a third through the presentation sounded like more of the ASM.

[wyattdog]

great presentation

[porkini]

There's a GAAP to Non-GAAP Reconciliations slide after the "Thank You" slide at the very end. Just FYI.

[porkini]

Middle of the road presentation, ranges from awful to great!

[esstan2001]

Q's-

2 years to get packaging correct like that was the big issue

dose clarity- wish they never were close in units; should have changed that to never intend correlation

data publication taking time.. getting sci data out there

managed care access..

MC relaunched many prods, this one his hardest

How to bend growth curve? T2 focus takes much work and $.

Focus on T1, patient care, etc effects to b seen Q3, we R excited, should see break in curve.

How Technosphere differ & benefit patients?

Unique, 1k patents

slower powder propagation so can deliver / release deep into lung

less side effect, less dosage

Migraine, dph

UTH collaboration future?

right partner, mkt leader, convert patient base to new inhaled product

long history between founders, Al helped save Martine's daughter(?)

Trepostinil... exciting

Cash burn, pandemic impact?

Salary / bonus cuts, PPP 4.9M

Q4 another milestone, CoH should be OK for 2020 into 21

what investments? sales force, telemed, patient hub

What catalysts?

aug /sept data sets ADA

UT pres in an hour..

filing for Tre-T

R&D pipeline, another partner

migraine dosing work..

other collaborations

grow faster Afrez sales